JP2005528374A5 - - Google Patents

Download PDF

Info

Publication number
JP2005528374A5
JP2005528374A5 JP2003581743A JP2003581743A JP2005528374A5 JP 2005528374 A5 JP2005528374 A5 JP 2005528374A5 JP 2003581743 A JP2003581743 A JP 2003581743A JP 2003581743 A JP2003581743 A JP 2003581743A JP 2005528374 A5 JP2005528374 A5 JP 2005528374A5
Authority
JP
Japan
Prior art keywords
alkyl
carbon atoms
group
amino
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003581743A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005528374A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2003/003434 external-priority patent/WO2003084503A2/en
Publication of JP2005528374A publication Critical patent/JP2005528374A/ja
Publication of JP2005528374A5 publication Critical patent/JP2005528374A5/ja
Pending legal-status Critical Current

Links

JP2003581743A 2002-04-05 2003-04-02 粘液分泌過多の治療方法 Pending JP2005528374A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02007699 2002-04-05
PCT/EP2003/003434 WO2003084503A2 (en) 2002-04-05 2003-04-02 P38 kinase inhibitors for treating mucus hypersecretion_

Publications (2)

Publication Number Publication Date
JP2005528374A JP2005528374A (ja) 2005-09-22
JP2005528374A5 true JP2005528374A5 (https=) 2006-06-01

Family

ID=28685842

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003581743A Pending JP2005528374A (ja) 2002-04-05 2003-04-02 粘液分泌過多の治療方法

Country Status (14)

Country Link
EP (1) EP1494645A2 (https=)
JP (1) JP2005528374A (https=)
KR (1) KR20040101398A (https=)
CN (1) CN1658834A (https=)
AU (1) AU2003224025A1 (https=)
BR (1) BR0309009A (https=)
CA (1) CA2479520A1 (https=)
IL (1) IL163737A0 (https=)
MX (1) MXPA04009605A (https=)
NZ (1) NZ536278A (https=)
PL (1) PL372963A1 (https=)
RU (1) RU2004132847A (https=)
WO (1) WO2003084503A2 (https=)
ZA (1) ZA200406910B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004101529A1 (ja) * 2003-05-19 2004-11-25 Ono Pharmaceutical Co., Ltd. 含窒素複素環化合物およびその医薬用途
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
WO2006137421A1 (ja) * 2005-06-21 2006-12-28 Kyowa Hakko Kogyo Co., Ltd. 局所投与剤
FR2903774B1 (fr) * 2006-07-17 2008-09-05 Renault Sas Procede de validation d'un diagnostic de fontionnement d'un dispositif.
MY159230A (en) 2008-10-02 2016-12-30 Respivert Ltd P38 map kinase inhibitors
GB0818033D0 (en) 2008-10-02 2008-11-05 Respivert Ltd Novel compound
JP5670912B2 (ja) 2008-12-11 2015-02-18 レスピバート・リミテツド p38MAPキナーゼ阻害剤
GB0905955D0 (en) 2009-04-06 2009-05-20 Respivert Ltd Novel compounds
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
WO2019071147A1 (en) 2017-10-05 2019-04-11 Fulcrum Therapeutics, Inc. INHIBITORS OF KINASE P38 REDUCING EXPRESSION OF DUX4 GENE AND DOWNSTREAM GENES FOR THE TREATMENT OF FSHD

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184226B1 (en) * 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
NZ528846A (en) * 1999-03-12 2005-05-27 Boehringer Ingelheim Pharma Compounds useful as anti-inflammatory agents
JP2003500403A (ja) * 1999-05-21 2003-01-07 サイオス,インコーポレーテッド p38キナーゼのインヒビターとしてのインドール型誘導体
HK1053107A1 (zh) * 1999-08-19 2003-10-10 Signal Pharmaceuticals, Inc. 作为jnk抗化剂的pyrazoloanthrone及其衍生物和它们的成份
AU7584500A (en) * 1999-09-17 2001-04-17 Smithkline Beecham Corporation Use of csaids in rhinovirus infection
EP1317450B1 (en) * 2000-09-15 2006-11-22 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
JP2004511542A (ja) * 2000-10-19 2004-04-15 スミスクライン・ビーチャム・コーポレイション 煙の吸入の治療のためのp38阻害剤の使用
MXPA03009361A (es) * 2001-04-13 2004-01-29 Boehringer Ingelheim Pharma Compuestos de urea utilies como agentes anti-inflamatorios.
TR200401028T2 (tr) * 2001-11-09 2004-11-22 Scios Inc. Kistik fibrozun tedavisine yönelik metot

Similar Documents

Publication Publication Date Title
RU2004133034A (ru) Новые фармацевтические композиции на основе антихолинергических средств и ингибиторов киназы р38
JP2005529098A5 (https=)
JP2002539198A5 (https=)
RU2001122111A (ru) Ароматические гетероциклические соединения в качестве противовоспалительных агентов
JP2004536845A5 (https=)
JP2003514808A5 (https=)
JP2005528374A5 (https=)
CA2352524A1 (en) Aromatic heterocyclic compounds as antiinflammatory agents
TW209867B (https=)
YU88491A (sh) Amidi izoksazol-4-karboksilne kiseline i amidi hidroksialkiliden-cijanosirćetne kiseline i postupak za dobijanje farmaceutskih preparata koji sadrže ta jedinjenja
CA2511970A1 (en) Urea derivatives useful in the treatment of heart failure
JP2005503400A5 (https=)
US20040110755A1 (en) Combination therapy with p38 MAP kinase inhibitors and their pharmaceutical compositions
JP2008509177A5 (https=)
RU2004132847A (ru) Способ лечения гиперсекреции слизи
WO2023001028A1 (zh) 杂芳-3-哌啶二酮类化合物及其应用
JP2020527575A5 (https=)
JP2005538066A5 (https=)
WO2009059030A1 (en) Pyrazole derivatives as kinase inhibitors
EP1545514A1 (en) Anticoagulant and fibrinolytic therapy using p38 map kinase inhibitors
US20030220336A1 (en) Method of treating mucus hypersecretion
TWI769395B (zh) 以吡唑并[3,4-d]嘧啶化合物為有效成分之治療劑
DE60310730T2 (de) Pharmazeutische zusammensetzungen aus anticholinergica und p38 kinase hemmern zur behandlung von erkrankungen der atemwege
JP2020015690A (ja) レボセチリジン含有錠剤
RU2021102256A (ru) Производные хиназолина биарилэфирного типа